Biotechnology
Innovent Receives NMPA Breakthrough Designation for IBI351 (KRASG12C Inhibitor) as Monotherapy for Previously Treated Advanced Colorectal Carcinoma
ROCKVILLE, Md. and SUZHOU, China, May 15, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and...
2023-05-15 08:00
3304
Access to Novavax's COVID Vaccine Grows with Extended Interim Authorization for Adolescents in Singapore
GAITHERSBURG, Md., May 12, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Singapore Health Sciences Authority (HSA) has granted extended interim authorization and the Ministry of Heal...
2023-05-12 21:01
5278
Results of Phase I Clinical Study of Qilu Pharma's PD-1/CTLA-4 Bifunctional Antibody Iparomlimab/Tuvonralimab Published Online in Journal of Hematology & Oncology
JINAN, China, May 12, 2023 /PRNewswire/ -- On May 8, 2023, Journal of Hematology & Oncology (JHO, 2022 impact factor of 23.168) published the results of the Phase I clinical study of Qilu Pharma's immunotherapy bifunctional antibody, QL1706 (J Hematol Oncol. 2023May 8;16(1):50). This study is the...
2023-05-12 17:40
2049
Nefecon Included in the Reimbursement Drug List of "Beijing Puhui Health Insurance Program" as a First-in-Disease Therapy for IgA Nephropathy
SHANGHAI, May 12, 2023 /PRNewswire/ -- An imported version of Nefecon (budesonide) delayed release capsule has been added to the 2023 New Reimbursement Drug List of Specialized Medicines of the "Beijing Puhui Health Insurance Program." Nefecon is a first-in-disease treatment for adults with prim...
2023-05-12 07:40
3854
Results of Phase I Clinical Study of Qilu Pharma's PD-1/CTLA-4 Bifunctional Antibody Iparomlimab/Tuvonralimab Published Online in Journal of Hematology & Oncology
JINAN, China, May 11, 2023 /PRNewswire/ -- On May 8, 2023, the authoritative oncology journal, Journal of Hematology & Oncology (JHO, 2022 impact factor of 23.168) published the results of the Phase I clinical study of Qilu Pharma's immunotherapy bifunctional antibody, QL1706 (Title: First-in-hum...
2023-05-11 20:55
2249
SHL Medical and MoonLake Immunotherapeutics collaborate to develop sonelokimab autoinjector
ZUG, Switerland, May 11, 2023 /PRNewswire/ -- SHL Medical, a world-leading provider of advanced drug delivery solutions, announced that it has signed a collaboration agreement with MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for inf...
2023-05-11 09:00
3221
Late-Breaking Turn Biotechnologies Presentation at ISID to Show Cell Reprogramming with ERA™ Technology Renews Skin
MOUNTAIN VIEW, Calif., May 10, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell reprogramming company developing novel mRNA medicines for untreatable, age-related conditions, has been invited to present data showing that its epigenetic reprogramming technology rejuvenates human skin. Turn Bio's...
2023-05-10 21:00
2363
Doceree forms an exclusive partnership with Hello Health Group to strengthen its global footprint; forays into 8 South East Asian markets
The partnership opens a first-of-its-kind service for Hello Health Group's
pharmaceutical clients,enabling them to target HCPs with precision and
efficiency
NEW DELHI, May 10, 2023 /PRNewswire/ -- Doceree
2023-05-10 11:00
2877
The China NMPA Approves TYVYT® (sintilimab injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-mutated Non-squamous NSCLC who Progressed after EGFR-TKI Therapy
ROCKVILLIE, Md. and SUZHOU, China, May 10, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic, ophthalmology and ...
2023-05-10 08:00
3463
Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting
FLORENCE, Italy and NEW YORK, May 9, 2023 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading Italian pharmaceutical and diagnostics company, and Stemline Therapeutics ("Stemline"), a wholly-owned subsidiary of the Menarini Group, announced today that they will present new data related to ...
2023-05-09 22:57
2728
Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses
* This Phase 2 trial is evaluating three vaccine candidates: COVID-Influenza Combination, stand-alone influenza and high-dose COVID * Preliminary topline immune responses for all three vaccine candidates were robust versus authorized comparators * For the stand-alone influenza vaccine candid...
2023-05-09 18:28
2592
IND Application for Phase Ⅲ Registration Study of KN026 in Combination with Chemotherapy for the First-line Treatment of Breast Cancer Was Approved by CDE
SUZHOU, China, May 9, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. jointly announced that the IND application was approved in China for the pivotal trial of the anti-HER2 bispecific antibody KN026 combined with Docetaxel (albumin-binding), i...
2023-05-09 10:00
2413
Hummingbird Bioscience to Present Preclinical Proof of Concept for Potentially First-In-Class Antibody Targeting Autoimmune Diseases
* HMBD-011 is a potentially first-in-class anti-VH4-34 antibody developed for treatment of VH4-34+ antibody-driven pathogenesis in lupus and cold agglutinin disease * Data presented shows preclinical proof of concept for HMBD-011 clearance of VH4-34+ antibodies and effective inhibition of col...
2023-05-08 18:30
1980
Ascletis Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection
--Respiratory syncytial virus (RSV) infection treatment remains huge unmet medical needs and there is no effective drug for treatment globally so far --Dosage of 800 mg ASC10, twice daily was selected to conduct a Phase IIa study in patients with RSV infection --Preclinical research showed that ...
2023-05-08 16:50
2458
Transcenta to Present Two Clinical Trial Progress at ASCO 2023
SUZHOU, China, May 8, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that two posters for c...
2023-05-08 14:55
2061
Bolivian and Taiwanese Experts Discuss the Latest Med-Tech Developments to Position Bolivia as a Leading hub in Robotic Neurosurgery
HSINCHU, May 8, 2023 /PRNewswire/ -- Medical experts from Bolivia and Taiwan recently joined forces to explore the latest technological advancements in surgical navigation robots and their potential to positionBolivia as a leader in robotic neurosurgery. During the largest robotic surgery online ...
2023-05-08 13:29
2260
Innovent Updates the Results from the ORIENT-31 Study of Sintilimab Plus Chemotherapy With or Without Bevacizumab in Patients with EGFR-TKI failed EGFR-mutated Non-Squamous Non-Small Cell Lung Cancer in the Lancet Respiratory Medicine
ROCKVILLE, Md. and SUZHOU, China, May 8, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2023-05-08 08:00
3854
Duoning Biotech Celebrates Ground Breaking for Its Global Headquarters
SHANGHAI, May 8, 2023 /PRNewswire/ -- On May 6th, the "2023 Commencement Ceremony for Major Industrial Projects in Fengxian and for Duoning's Global Headquarters and Industrialization Base" was held grandly in the Biotechnology Park. Leaders of the Fengxian district, representatives of the Orient...
2023-05-08 08:00
2190
Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study
MELBOURNE, Australia, May 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement with Bayer AG (Bayer) to supply Illuccix® (TLX591-CDx, kit for the preparation of gallium Ga 68 gozetotide injection)[1] for the Pha...
2023-05-08 05:00
5286
Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study, including Japanese Sites
MELBOURNE, Australia and KYOTO, Japan, May 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement with Bayer AG (Bayer) to supply Illuccix® (TLX591-CDx, kit for the preparation of gallium Ga 68 gozetotide injectio...
2023-05-08 05:00
2236
Week's Top Stories
Most Reposted
Troy Animal Healthcare Strengthens Quality Operations with Veeva Vault Quality
[Picked up by 321 media titles]
2024-05-17 07:00Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 319 media titles]
2024-05-15 12:00
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 303 media titles]
2024-05-16 15:00
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 274 media titles]
2024-05-16 09:39
Trip.com Group and Rezdy Join Forces to Offer New Travel Experiences Around the World
[Picked up by 229 media titles]
2024-05-14 18:07Most Read
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
2024-05-15 12:00
8263
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
2024-05-16 15:00
6458
Traveloka strengthens sustainability pledge as world's first Platinum Sponsor of GSTC
2024-05-13 16:42
6406
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
2024-05-16 09:39
6176
Casio to Release G-SHOCK-Surfrider Foundation Collaboration
2024-05-15 09:00
6139
